Paper - WANFANG MED ONLINE

You Position: Home > Paper

The optimal use of glucocorticoids for patients with chronic obstructive pulmonary disease: a Chinese expert consensus(2021)

( views:624, downloads:378 )

Author:: No author available

Journal Title:: Chinese Journal of Tuberculosis and Respiratory Diseases

Issue:: 12

DOI:: 10.3760/cma.j.cn112147-20210802-00543

Key Word:: No keyword available

Abstract：慢性阻塞性肺疾病（慢阻肺）是我国需要重点防治的慢性呼吸系统疾病之一，糖皮质激素规范应用在慢阻肺治疗中具有重要作用。在循证证据和临床经验的基础上，结合中国慢阻肺糖皮质激素应用现状，围绕慢阻肺稳定期初始治疗、随访期调整治疗，根据患者临床症状特征、急性加重风险、合并哮喘、支气管扩张（症）和肺结核病、外周血嗜酸粒细胞等指标判断是否需要联合和停用糖皮质激素治疗，根据慢阻肺急性加重异质性，选择糖皮质激素给药途径、剂量和疗程，撰写组提出7条推荐意见，以进一步推动不同级别医院特别是基层医疗机构医务人员落实中国慢阻肺指南中糖皮质激素在慢阻肺个体化治疗的临床实践。

Reference

[1]张敏.慢性阻塞性肺疾病表型临床意义的研究进展[J].2016,(1).
[2]崔令花,刘超.慢性阻塞性肺疾病急性加重的异质性及个体化治疗[J].2017,(5).
[3]中国物联网辅助雾化吸入治疗专家组.物联网辅助雾化吸入治疗中国专家共识[J].2017,(10).
[4]中华医学会临床药学分会《雾化吸入疗法合理用药专家共识》编写组.雾化吸入疗法合理用药专家共识（2019年版）[J].2019,(2).
[5]吴蕾,许凡凡,关英慧,等.吸入性糖皮质激素对稳定期COPD获益及风险的meta分析[J].2017,(4).
[6]中国医师协会急诊医师分会,中国人民解放军急救医学专业委员会,北京急诊医学学会,等.雾化吸入疗法急诊临床应用专家共识（2018）[J].2018,(7).
[7]饶敏,潘颖超,董甲贵,等.慢性阻塞性肺疾病急性加重期临床表型的异质性分析[J].2019,(12).
[8]曾莹莹,张静.吸入糖皮质激素与肺部感染[J].2018,(5).
[9]成人慢性气道疾病雾化吸入治疗专家组.成人慢性气道疾病雾化吸入治疗专家共识[J].2012,(2).
[10]吴玉华,林军伟,周建,等.物联网医学在呼吸系统疾病诊治与管理中的应用现状[J].2017,(26).
[11]冯玉麟,欧雪梅,唐永江.重视慢性阻塞性肺疾病急性加重的异质性及其个体化诊治[J].2014,(4).
[12]潘明鸣,孙铁英,王辰.慢性阻塞性肺疾病治疗反应相关的临床表型分型及其特点[J].2013,(4).
[13]慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组.慢性阻塞性肺疾病急性加重（AECOPD）诊治中国专家共识（2017年更新版）[J].2017,(14).
[14]刘红梅,乌云高娃.慢性阻塞性肺疾病合并支气管扩张患者的肺功能评价[J].2020,(36).
[15]兰平起,黄慧俐,刘朝伟,等.糖皮质激素序贯治疗在AECOPD并呼吸衰竭患者中的应用[J].2010,(12).
[16]陈亚红.慢性阻塞性肺疾病稳定期药物维持治疗[J].2019,(4).
[17]中国医学装备协会呼吸病学专委会吸入治疗与呼吸康复学组,中国慢性阻塞性肺疾病联盟.稳定期慢性气道疾病吸入装置规范应用中国专家共识[J].2019,(4).
[18]中华医学会呼吸病学分会《雾化吸入疗法在呼吸疾病中的应用专家共识》制定专家组.雾化吸入疗法在呼吸疾病中的应用专家共识[J].2016,(34).
[19]Fekri Abroug,Lamia Ouanes-Besbes,Mohamed Fkih-Hassen,etc.Prednisone in COPD exacerbation requiring ventilatory support: an open-label randomised evaluation.[J].2014,43(3).
[20]"ORCID":"http:\/\/orcid.org\/0000-0002-8620-3655Pradeesh Sivapalan,Truls Sylvan Ingebrigtsen,Daniel Bech Rasmussen,etc.COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months[J].2019,6(1).
[21]David M G Halpin,Gerard J Criner,Alberto Papi,etc.Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease.[J].2021,203(1).
[22]Jacquemet N,Maltais F,Bourbeau J,etc.Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.[J].2002,165(5).
[23]Taylor, Glyn,Warren, Simon,Dwivedi, Sarvajna,etc.Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology[J].2018,111.
[24]Lechuga Ballesteros D,Noga B,Dwivedi SK,etc.Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma.[J].2011,3(13).
[25]Tobias, Welte,Marc, Miravitlles,Paul, Hernandez,etc.Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.[J].2009,180.
[26]Ian A, Yang,Melissa S, Clarke,Esther H A, Sim,etc.Inhaled corticosteroids for stable chronic obstructive pulmonary disease.[J].2012.
[27].慢性阻塞性肺疾病诊治指南（2021年修订版）[J].2021,(3).
[28]JOSEPH J. CROWLEY,NIRMAL B. CHARAN,WILLIAM H. THOMPSON,etc.Controlled Trial of Oral Prednisone in Outpatients with Acute COPD Exacerbation[J].1996,154(2 Pt.1).
[29]Reisner, Colin,Martinez, Fernando J.,Aurivillius, Magnus,etc.Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled tr[J].2018,6(10).
[30]Noga, B.,Vehring, R.,Dwivedi, S.K.,etc.Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers[J].2012,28(42).
[31]Papi, Alberto,Vestbo, Jorgen,Fabbri, Leonardo,etc.Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial[J].2018,391(10125).
[32]Richard N,Dalby.Development of Respimat(?) Soft Mist? Inhaler and its clinical utility in respiratory disorders.[J].2011,4.
[33]Aleksandra, Dudvarski Ilic,Vladimir, Zugic,Biljana, Zvezdin,etc.Influence of inhaler technique on asthma and COPD control: a multicenter experience.[J].2016,(Spec ).
[34]D E, Niewoehner,M L, Erbland,R H, Deupree,etc.Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group.[J].1999,340(25).
[35]G, Horvath,A, Wanner.Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma.[J].2006,27(1).
[36]Thompson, Philip J.,Frenzel, Christina,Kurstjens, Nicol,etc.Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN studya randomised controlled trial[J].2015,70(6).
[37]Song IH,Buttgereit F.Non-genomic glucocorticoid effects to provide the basis for new drug developments.[J].2006,246(1).
[38].Single-Inhaler Triple versus Dual Therapy in Patients with COPD.[J].2018,379(6).
[39]房玉萍.老年慢阻肺合并肺结核感染患者的诊断措施及治疗方式分析[J].2019,(A3).
[40]Iwanaga Takashi,Kozuka Takenori,Nakanishi Junko,etc.Aerosol Deposition of Inhaled Corticosteroids/Long-Acting β2-Agonists in the Peripheral Airways of Patients with Asthma Using Functional Respiratory Imaging, a Novel Imaging Technology[J].2017,3(1).
[41]Niewoehner,D.E.,O'Dell,D.M.,Crater,G.D.,etc.Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD[J].2012,106(1).
[42]Gary, Pitcairn,Sandie, Reader,Demetri, Pavia,etc.Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler.[J].2005,18(3).
[43]Kenneth R, Chapman,John R, Hurst,Stefan-Marian, Frent,etc.Long-term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in COPD Patients (SUNSET): a Randomized, Double-Blind, Triple-Dummy Clinical Trial.[J].2018,(Spec ).
[44]J Andrew, Woods,James S, Wheeler,Christopher K, Finch,etc.Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease.[J].2014,9.
[45]Siler, Thomas M.,Kerwin, Edward,Singletary, Karen,etc.Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies[J].2016,13(1).
[46]Daniel C,Lane,Stephen,Stemkowski,Richard H,Stanford,etc.Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U.S. Retrospective Database Study.[J].2018,24(11).
[47]Goeminne,P.C.,Nawrot,T.S.,Ruttens,D.,etc.Mortality in non-cystic fibrosis bronchiectasis: A prospective cohort analysis[J].2014,108(2).
[48]Lowie,Vanfleteren,Leonardo M,Fabbri,Alberto,Papi,etc.Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.[J].2018,13.
[49]Linda,Nici,Manoj J,Mammen,Edward,Charbek,etc.Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline.[J].2020,201(9).
[50]孙婉璐,陈亚红.慢性阻塞性肺疾病急性加重糖皮质激素应用现状与依据[J].2018,(5).
[51]Hagan G,Brooks J,O'Connor BJ,etc.Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.[J].2008,63(7).
[52]Lomas, David A.,Mohindra, Rajat,Lipson, David A.,etc.FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease[J].2017,196(4).
[53]中华医学会,中华医学会临床药学分会,中华医学会杂志社,等.慢性阻塞性肺疾病基层合理用药指南[J].2020,19(8).
[54]赵美芳,宋昱晨,王月花.慢性阻塞性肺疾病并发肺部感染的影响因素与病原学检测分析[J].2017,(4).
[55]L Davies,RM Angus,PMA Calverley.Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial[J].1999,354(9177).
[56]贾国华,陈亚红.2017年西班牙慢性阻塞性肺疾病指南解读[J].2017,(12).
[57]Harnett, C. M.,Hunt, E. B.,Bowen, B. R.,etc.A study to assess inhaler technique and its potential impact on asthma control in patients attending an asthma clinic[J].2014,51(4).
[58]Marc Miravitlles,Juan José Soler-Cataluña,Myriam Calle,etc.Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable[J].2017,53(6).
[59]Lipson, David A.,Barnhart, Frank,Brealey, Noushin,etc.Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD[J].2018,378(18).
[60]David M.G. Halpin,Hilda J.I. de Jong,Victoria Carter,etc.Distribution, Temporal Stability and Appropriateness of Therapy of Patients With COPD in the UK in Relation to GOLD 2019[J].2019,14.
[61]Calzetta, Luigino,Di Marco, Fabiano,Blasi, Francesco,etc.Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis[J].2019,59.
[62]Magnussen,H.,Disse,B.,Rodriguez-Roisin,R.,etc.Withdrawal of inhaled glucocorticoids and exacerbations of COPD[J].2014,371(14).
[63]Kim,S.K.,Lee,S.D.,Jung,K.S.,etc.Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: A randomized controlled study[J].2012,106(3).
[64]Bafadhel, Mona,Pavord, Ian D.,Russell, Richard E. K..Eosinophils in COPD: just another biomarker?[J].2017,5(9).
[65]Samy Suissa,Sophie Dell'Aniello,Pierre Ernst.Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study[J].2018,6(11).
[66]王小虎,詹丹婷,陈荣昌,等.2020年欧洲呼吸学会慢性阻塞性肺疾病撤除吸入糖皮质激素的指南要点解读[J].2021,(2).